Brokerages Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Price Target at $130.08

Abivax SA Sponsored ADR (NASDAQ:ABVX) has received a consensus recommendation of “Moderate Buy” from the fifteen analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $130.0769.

A number of analysts have commented on the stock. Barclays increased their price target on shares of Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. Morgan Stanley cut their price target on shares of Abivax from $145.00 to $132.00 and set an “overweight” rating for the company in a research note on Tuesday, June 2nd. Truist Financial cut their price target on shares of Abivax from $140.00 to $135.00 and set a “buy” rating for the company in a research note on Tuesday, June 2nd. Wedbush upgraded shares of Abivax from an “underperform” rating to a “neutral” rating and cut their price target for the company from $110.00 to $90.00 in a research note on Tuesday, June 2nd. Finally, Wolfe Research set a $136.00 price target on shares of Abivax in a research note on Wednesday, June 3rd.

Abivax Stock Up 2.7%

ABVX stock opened at $100.15 on Friday. The business has a 50 day moving average price of $114.81 and a two-hundred day moving average price of $118.49. The company has a market cap of $7.99 billion, a price-to-earnings ratio of -19.22 and a beta of 0.69. Abivax has a twelve month low of $5.69 and a twelve month high of $148.83.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to the consensus estimate of $0.40 million. On average, equities research analysts anticipate that Abivax will post -3.4 EPS for the current fiscal year.

Institutional Trading of Abivax

Hedge funds have recently made changes to their positions in the business. Jefferies Financial Group Inc. acquired a new stake in shares of Abivax in the third quarter valued at approximately $38,827,000. Persistent Asset Partners Ltd acquired a new stake in shares of Abivax in the third quarter valued at approximately $815,000. Nan Fung Trinity HK Ltd. lifted its stake in shares of Abivax by 11.8% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 113,365 shares of the company’s stock worth $15,288,000 after buying an additional 12,000 shares during the last quarter. Atika Capital Management LLC acquired a new stake in shares of Abivax during the 3rd quarter worth about $5,858,000. Finally, Total Clarity Wealth Management Inc. acquired a new stake in shares of Abivax during the 4th quarter worth about $1,247,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.